| FBW7 is a novel tumor suppressor in T cell leukemia, and its loss may be a potential mechanism of drug resistance in T-ALL | leukemia, |
| The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. | breast, |
| The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. | leukemia, |
| Our data provides evidence on FBXW7 as a critical tumor suppressor mutated and inactivated in melanoma that results in sustained NOTCH1 activation and renders NOTCH signaling inhibition as a promising therapeutic strategy in this setting. | skin, |
| sequential expression of miR-182 and miR-503 in benign adenoma cooperatively regulates the tumour suppressor FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma | colorectal, |
| Results collectively demonstrate how the oncogenic KRAS mutation inhibits the tumor suppressor FBW7, thus revealing an important function of KRAS mutations in promoting pancreatic cancer progression. | pancreatic, |
| FBXW7 is a significant tumor suppressor gene in renal cancer.FBXW7 overexpression suppresses renal cancer cell proliferation and induces apoptosis. | kidney, |
| Dependence of Human Colorectal Cells Lacking the FBW7 Tumor Suppressor on the Spindle Assembly Checkpoint | colorectal, |
| Study provides evidence that the tumor suppressor Fbxw7alpha is the E3 ubiquitin ligase responsible for the degradation of SOX10, and suggests that reduced Fbxw7alpha might contribute to the upregulation of SOX10 in melanoma cells. | skin, |
| This study suggests that FBXW7, normally a tumor suppressor, can act as an oncogene when mutated and may play an important role in the pathogenesis of adult T-cell leukemia. | leukemia, |
| Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting ?-catenin for degradation in pancreatic cancer | pancreatic, |
| Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7), and cadherin-6 (CDH6) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR-129-2 and members of the miR-200 family (miR-200a, miR-200b, and miR-429) as novel tumor suppressors and oncomiRs, respectively, in CC | liver,cholangiocarcinoma, |
| EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor | breast, |
| FBXW7, a tumor suppressor, inhibits breast cancer cell proliferation and promotes apoptosis at least partially through targeting MTDH for proteolysis | breast, |
| FBXW7 conduction of tumour suppression was partly through degrading Snai1 directly for ubiquitylating regulation in NSCLC. | lung, |
| Brg1 is a bona fide ubiquitin substrate of SCF(FBW7). In keeping with a tumor suppressive role of FBW7 in human gastric cancer, we find an inverse correlation between FBW7 and Brg1 expression in human gastric cancer clinical samples. Mechanistically, we find that stabilization of Brg1 in gastric cancer cells suppresses E-cadherin expression, subsequently promoting gastric cancer metastasis. | gastric, |
| The present study demonstrated that PRMT5 epigenetically silenced the expression of the tumor suppressor FBW7, leading to increased cMyc levels and the subsequent enhancement of the proliferation of and aerobic glycolysis in pancreatic cancer cells. | pancreatic, |
| The tumor suppressive function of FBXW7 in gastric cancer.GSK3B controls GFI1 expression via phosphorylation of Serine 94 and Serine 98 sites, which leads to SCFFBXW7-mediated polyubiquitination and proteasome degradation. | gastric, |
| N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor | colorectal, |
| Alteration in Expression of miR-32 and FBXW7 Tumor Suppressor in Plasma Samples of Patients with T-cell Acute Lymphoblastic Leukemia | leukemia, |